OZOBAX Drug Patent Profile
✉ Email this page to a colleague
When do Ozobax patents expire, and what generic alternatives are available?
Ozobax is a drug marketed by Metacel Pharms Llc and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in OZOBAX is baclofen. There are twenty-one drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the baclofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ozobax
A generic version of OZOBAX was approved as baclofen by IVAX SUB TEVA PHARMS on July 21st, 1988.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OZOBAX?
- What are the global sales for OZOBAX?
- What is Average Wholesale Price for OZOBAX?
Summary for OZOBAX
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 150 |
| Patent Applications: | 3,907 |
| What excipients (inactive ingredients) are in OZOBAX? | OZOBAX excipients list |
| DailyMed Link: | OZOBAX at DailyMed |
Pharmacology for OZOBAX
| Drug Class | gamma-Aminobutyric Acid-ergic Agonist |
| Mechanism of Action | GABA A Agonists GABA B Agonists |
US Patents and Regulatory Information for OZOBAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Metacel Pharms Llc | OZOBAX | baclofen | SOLUTION;ORAL | 208193-001 | Sep 18, 2019 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Metacel Pharms Llc | OZOBAX DS | baclofen | SOLUTION;ORAL | 208193-002 | Oct 12, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
